Welcome to our dedicated page for Boston Scien Cp SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Boston Scientific Corporation (NYSE: BSX) files a broad range of reports and disclosures with the U.S. Securities and Exchange Commission, providing detailed insight into its operations as a global medical technology company. These SEC filings cover topics such as financial performance, material acquisitions, executive compensation programs, governance changes and risk factors relevant to the business.
On this page, you can review Boston Scientific’s current reports on Form 8-K, which the company uses to announce material events. Recent 8-K filings describe the definitive agreement to acquire Penumbra, Inc., including references to a joint press release and investor presentation, as well as the adoption of a 2026 annual bonus plan and performance share programs tied to metrics like global sales, adjusted earnings per share, relative total shareholder return and organic net sales growth. Other 8-Ks report quarterly financial results, director retirement plans and changes in senior leadership roles.
In addition to 8-Ks, Boston Scientific’s annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system) include consolidated financial statements, segment and geographic net sales data, discussions of MedSurg and Cardiovascular businesses, and extensive risk factor sections. These filings also explain the company’s use of non-GAAP financial measures such as operational and organic net sales growth and adjusted earnings per share, with reconciliations to GAAP figures.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on acquisitions, compensation plans, performance metrics and risk disclosures. Real-time updates from EDGAR ensure that new Boston Scientific filings, including Forms 10-K, 10-Q and 4 (insider transaction reports), are added as they become available, while AI-generated explanations assist in interpreting complex financial and legal language.
Boston Scientific Corp. Form 144 notice reports a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $5,271,415.00, with an approximate sale date of 09/02/2025. The filing states these 50,000 shares were acquired the same day by stock option exercise and paid for in cash.
The filing also discloses prior sales by the same person, JOSEPH M FITZGERALD, totaling 156,372 shares across three transactions on 06/04/2025, 07/01/2025, and 08/01/2025, generating gross proceeds of $16,985,599.64 combined. The notice includes the seller's representation that no undisclosed material adverse information is known.
FAQ
What is the current stock price of Boston Scien Cp (BSX)?
What is the market cap of Boston Scien Cp (BSX)?
